{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.6","upperLimit":"7.0","value":"5.8"},{"groupId":"OG001","lowerLimit":"4.2","upperLimit":"7.0","value":"5.5"}]}],"title":"BICR"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.7","upperLimit":"7.0","value":"5.8"},{"groupId":"OG001","lowerLimit":"4.2","upperLimit":"8.3","value":"5.7"}]}],"title":"Investigator"}],"denoms":[{"counts":[{"groupId":"OG000","value":"82"},{"groupId":"OG001","value":"40"}],"units":"Participants"}],"description":"Progression Free Survival (PFS) defined as the time from date of randomization/registration until first objective radiographic tumor progression or death from any cause, based on BICR and Investigator assessment according to RECIST version 1.1. PFS was assessed in the Full Analysis Set at data cut-off date of 01 Nov 2022.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants were randomized to receive intravenous T-DXd administered at a dose of 5.4 mg/kg every 3 weeks (Q3W).","id":"OG000","title":"T-DXd 5.4 mg/kg Q3W"},{"description":"Participants were randomized to receive intravenous T-DXd administered at a dose of 6.4 mg/kg every 3 weeks (Q3W).","id":"OG001","title":"T-DXd 6.4 mg/kg Q3W"}],"paramType":"MEDIAN","populationDescription":"PFS was assessed in the Full Analysis Set, which included 1 participant who was randomized/registered to T-DXd 6.4 mg/kg Q3W but actually received T-DXd 5.4 mg/kg Q3W.","reportingStatus":"POSTED","timeFrame":"From randomization to data cut off, up to approximately 19 months.","title":"Progression Free Survival Following Intravenous Administration of T-DXd in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Overexpressing Metastatic Colorectal Cancer","type":"SECONDARY","unitOfMeasure":"month"}